Business Development

The basis of Medeia’s success lies on scientific leadership in our key therapeutic areas, capable and committed people with strong entrepreneurial spirit, and valued partnerships. Because we focus on the discovery and early development of innovative products, building strong partnerships with experienced pharmaceutical and biotech companies backed by clinical research and commercialization capabilities as well as financial strength and stability is a high priority for us.

We are also interested in in-licensing of early stage projects (compounds or drug targets) and building external research collaborations with academia and other biotech companies for gaining further mechanistic understanding on pathogenic processes of neurodegenerative diseases. Medeia welcomes contacts from academia, inventors and other biotechnology companies to discuss seed-stage projects with strong IPR position in the field of CNS diseases.